Rhabdomyolysis caused by candesartan cilexetil
10.3760/cma.j.cn114015-20210108-00034
- VernacularTitle:坎地沙坦酯致横纹肌溶解症
- Author:
Qin DING
1
;
Chendong YANG
Author Information
1. 中国人民武装警察部队特色医学中心内分泌科，天津 300171
- Publication Type:Journal Article
- Keywords:
Antihypertensive agents;
Rhabdomyolysis;
Candesartan cilexetil
- From:
Adverse Drug Reactions Journal
2021;23(10):557-558
- CountryChina
- Language:Chinese
-
Abstract:
A 74-year-old female patient was chronically treated with insulin glargine injection, insulin aspart injection, metformin tablets, and nifedipine controlled-release tablets because of type 2 diabetes mellitus and hypertension. Due to poor blood pressure control, candesartan cilexetil 8 mg orally once daily was added. Five days later, the patient developed myalgia and fatigue. Laboratory tests showed myoglobin >2 000 μg/L, creatine kinase 8 567 U/L, creatine kinase MB 279 U/L, aspartate aminotransferase 273 U/L, lactate dehydrogenase 546 U/L, alpha hydroxybutyrate dehydrogenase 498 U/L, and positive protein and occult blood in urine. Rhabdomyolysis caused by candesartan cilexetil was considered. Then the drug was discontinued and symptomatic treatments such as rehydration, alkalinized urine, and diuretics were given. After 7 days of drug withdrawal, the patient′s symptoms were relieved, and after 10 days of drug withdrawal, the laboratory indexes such as myoglobin, creatine kinase, and aspartate aminotransferase returned to normal.
